SCHEMBL19729337

SCHEMBL19729337

CC(C)N(C(C)C)C(CCCNC(=N)N)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.37
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
ITGB3 P05106 4/20 0.33
ITGA2B P08514 4/20 0.33
OTC P00480 1/20 0.32
NPY4R P50391 5/20 0.32
NPY1R P25929 3/20 0.32
NPY2R P49146 3/20 0.32
NPY5R Q15761 3/20 0.32
EPHX1 P07099 1/20 0.32
ALB P02768 1/20 0.31
DDAH1 O94760 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22384113 0.90 ALOX15 (0.33) ALOX15MEN1KMT2AGAANOS3
SCHEMBL19729248 0.88 ALOX15 (0.37) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL23222830 0.86 ALOX15 (0.36) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL196827 0.84 NOS2 (0.38) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL288819 0.84 NOS2 (0.38) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL29770073 0.84 NOS2 (0.38) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL3377211 0.84 ALOX15 (0.36) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL160690 0.84 NOS2 (0.38) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL3377213 0.84 ALOX15 (0.36) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL995563 0.84 NOS2 (0.38) ALOX15MEN1KMT2ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183253-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL 2023-06-15 US disclosed
US-20230183253-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL 2023-06-15 US disclosed
EP-3804725-A2 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY Rhode Island Hospital (US) 2021-04-14 EP disclosed
EP-3220914-B1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL (US) 2020-09-02 EP disclosed
US-20170362238-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL 2017-12-21 US disclosed
US-20170362238-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362238-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY POLRMT, NT5C3B, CHMP4B ALOX15 4531/4885MEN1 125/4885KMT2A 2925/4885
US-20230183253-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY POLRMT, NT5C3B, CHMP4B ALOX15 4531/4885MEN1 125/4885KMT2A 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.